This is the authors' abstract. We don't add key points for this paper.
The immunogenicity of COVID-19 vaccines in maintenance hemodialysis (MHD) and kidney transplant recipients (KTR) are suboptimal. However, there are no data on the durability of the humoral response with the ChAdOx1 nCoV-19 vaccine in these groups. This was a multicenter, prospective cohort study of MHD patients (n = 73), KTR (n = 62), and controls (n = 22) who received the ChAdOx1 nCoV-19 vaccine between February 2021 and April 2022. The vaccine response was measured at 1 and 6 months after the second dose. The antibody response in the MHD group compared with the controls was statistically lower at both 1 and 6 months. However, only six (8.2%) cases showed negative seroresponses at 1 month, and five (6.84%) had negative responses at 6 months. For the KTR group, overall, 26 (35.61%) cases had no seroresponse, and 36 (64.39%) seroconverted at6 months. In this group, antibody levels were lower at 6 months; however, there was no significant difference compared with 1 month. In a comparison of the MHD group and KTR, the antibody levels were significantly lower in the KTR group. The risk factors for no response at 6 months in the KTR group were a greater age, a recent history of antirejection, and being in the early transplant period, whereas only age was linked with a low response in the MHD group. Our report highlights the consistent and durable response of the COVID-19 vaccine in both groups of patients, despite them having an attenuated response compared with the controls.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Meshram et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: